BMS Pulls Ahead of Amgen, Aces Confirmatory Phase III NSCLC Trial for Krazati

Bristol Myers Squibb on Thursday released results from the Phase III KRYSTAL-12 study, showing that Krazati (adagrasib) met its primary efficacy endpoint of progression-free survival in patients with locally advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.